Insight

Sabine D. Brookman-May: Excellent coverage on lymph-node-only metastatic urothelial cancer

Photo taken from Sabine D. Brookman-May/X

Jun 6, 2024, 06:52

Sabine D. Brookman-May: Excellent coverage on lymph-node-only metastatic urothelial cancer

Sabine D. Brookman-May, Professor of Urology at Munchen University, shared a post by UroToday.com on X, adding:

“Excellent coverage on lymph-node-only metastatic urothelial cancer as a distinct entity among complete responders to Nivo/GC.

Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58).”

Quoting UroToday.com’s post:

“Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from CheckMate 901. Presented by Matt Galsky.”

Read further
Sources: Sabine D. Brookman-May/X and UroToday.com/X

ASCO ASCO24 cancer CheckMate 901 gemcitabine-cisplatin lymph-node-only metastatic urothelial cancer Matt Galsky Nivo/GC nivolumab + gemcitabine-cisplatin OncoDaily Oncology Sabine D. Brookman-May urothelial cancer urothelial carcinoma

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer